Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 3;7:63. doi: 10.3389/fonc.2017.00063

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Abdo, Agrawal and Mittal.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Visualize esophageal cancer therapeutic targets with 9-marker panel. Proteomic biomarkers affiliated with improved response to targeted therapy (green) or chemotherapy (red) drugs as well as resistance to various chemotherapeutic agents that are FDA approved for esophageal cancer (EC). Knowing the expression status of this 9-marker panel could assist oncologists in optimizing first-line patient management strategies for EC patients. Abbreviations: ERCC1, excision repair cross complementation group 1; TUBB3, tubulin beta-3; TOPO2A, topoisomerase 2α; TOPOI, type I topoisomerase; HER2, receptor tyrosine-protein kinase erbB-2; EGFR, epidermal growth factor receptor could assist; PD-L1, programmed death-ligand 1; RFC, reduced folate carrier; TS, thymidylate synthase.